Nova assets not so certain about your scam theory there
Throughout our conversation, Dr. Mohammadi’s passion and enthusiasm about her research was infectious and her objective moving forward is clear. The potential market for psilocybin might grow exponentially as a result of Mohammadi’s research to include a new segment for psilocybin therapy. If successful, Mohammadi’s research could prove the merits of microdosing psilocybin in appetite regulation, without hallucinogenic effects, while also solving mood altering effects through alterations in the microbiome.
We should also tell you, Dr. Mohammadi did mention the potential for her research to improve the psilocybin molecule for the purpose of improving the microdose outcome but she would not elaborate on this subject. If Mohammadi were able to achieve this feat, and her research proved her hypothesis, in 3-5 years, Liberty Leaf’s acquisition of Nova Mentis today on June 22nd will look like a genius move. For full disclosure, today we bought $LIB stock today, after our discussion with the doctor, and we look forward to bringing our readers future updates on her progress.
Stock Action
After Liberty Leaf’s announcement of the psilocybin deal, $LIB traded ten times its normal daily volume, and it seems many of the weak hands in the stock were shaken out into stronger hands, with smart money accumulating. We expect this trend to continue as the company begins to talk about its new future, and investors learn what we learned today. It is also important to note that it appears Nova Mentis will not face the same issue as Champignon’s failure to publish a Business Acquisition Report (BAR) as there were $6,584,935 in assets as of the last audited financials, so the acquisition would not exceed the asset threshold requirement.
https://mushroomstockindex.com/article/discussion-with-dr-aylia-mohammadi-of-nova-mentis/